marked.bio

RAS:PI3Kα interaction blocker · small molecule

BBO-10203

3 active trials across 3 of our biomarkers, targeting RAS-PI3Kα. Not approved for any biomarker on marked.bio yet.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
KRAS G12C 3 3 Phase 1
KRAS G12D 2 2 Phase 1
PIK3CA activating mutation 1 1 Phase 1

Sponsors

Industry sponsors leading active biomarker-selected trials of BBO-10203.

  1. BridgeBio Oncology Therapeutics 3

Trials

3 of 3 trials shown

  1. BBO-11818 in Adult Subjects With KRAS Mutant Cancer

    Recruiting Phase 1 BridgeBio Oncology Therapeutics Started 2025Primary completion 2027-08 NCT06917079

    BBO-11818pembrolizumabcisplatincarboplatinpemetrexedcetuximabmFOLFOX6BBO-10203mFOLFIRINOXgemcitabinenab-paclitaxel

    …ced and unresectable or metastatic NSCLC, PDAC, CRC, or other solid tumor with KRAS G12A, G12C, G12D, G12S, or G12V mutation

    KRAS G12CKRAS G12DNon-Small Cell Lung Cancer, NSCLC, PDAC - Pancreatic Ductal Adenocarcinoma, CRC (Colorectal Cancer)

  2. Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

    Recruiting Phase 1 BridgeBio Oncology Therapeutics Started 2024Primary completion 2031-04 NCT06343402

    BBO-8520pembrolizumabBBO-10203

    …umented locally advanced and unresectable or metastatic non-small cell lung cancer with a KRAS G12C mutation

    KRAS G12CNon-small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer, NSCLC, KRAS G12C

  3. Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

    Recruiting Phase 1 BridgeBio Oncology Therapeutics Started 2024Primary completion 2028-11 NCT06625775

    BBO-10203trastuzumabfulvestrantribociclibFOLFOXbevacizumab

    …-positive advanced breast cancer (aBC), HR-positive/HER2-negative advanced breast cancer, KRAS mutant advanced colorectal cancer (aCRC), or KRAS mutant advanced non-small cell lung cancer (aN…

    KRAS G12CKRAS G12DPIK3CA activating mutationSolid Tumor, Adult, Metastatic Breast Cancer, Advanced Breast Cancer, HER2 Mutation-Related Tumors